TG Ther­a­peu­tic­s' shares jump as um­bral­is­ib wins FDA's break­through sta­tus

About a month af­ter the pub­li­ca­tion of en­cour­ag­ing re­sults from an ear­ly-stage study eval­u­at­ing J&J’s Im­bru­vi­ca in com­bi­na­tion with its ex­per­i­men­tal drug um­bral­is­ib, TG Ther­a­peu­tics on Tues­day said the drug has been grant­ed the FDA’s break­through ther­a­py sta­tus for use in pa­tients with mar­gin­al zone lym­phoma (MZL), a type of can­cer with no specif­i­cal­ly ap­proved ther­a­pies.

The New York-based com­pa­ny’s stock $TGTX jumped about 12% in pre-mar­ket trad­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.